Page 179 - AI for Good Innovate for Impact

AI for Good Innovate for Impact

2 Use Case Summary Table

2�1 Description

The AI-Enhanced Organoid Platform aims to revolutionize pandemic preparedness and 4.1-Healthcare
personalized medicine by leveraging cutting-edge AI technologies. It integrates 3D organoid
models with deep learning algorithms to simulate human respiratory tract responses, predict
viral mutations, and optimize drug discovery processes.

Problem to Solve:
1) Inefficient Drug Screening: Traditional methods for respiratory virus drug testing are slow
and costly, delaying critical treatments during outbreaks.
2) Unpredictable Viral Evolution: Current tools cannot accurately forecast high-risk viral
variants, hindering proactive vaccine development.
3) Limited Access to Personalized Medicine: Developing regions lack affordable, tailored
treatments for respiratory diseases.

AI Approach:
• Organoid Simulation: Train deep learning models on 3D organoid data to replicate
human respiratory tract responses to pathogens like COVID-19 and influenza.
• Viral Mutation Prediction: Use generative AI to analyze viral genome sequences and
predict high-risk mutations, enabling preemptive vaccine design.
• Automated Monitoring: Develop AI-powered image analysis tools for non-invasive
organoid monitoring, reducing manual labor and improving accuracy.

Benefits:

• Accelerated Drug Discovery: Reduce drug screening timelines by 50%, enabling faster
responses to pandemics.
• Proactive Vaccine Design: Achieve 90% accuracy in predicting viral mutations, minimizing
outbreak risks.
• Personalized Medicine: Provide low-cost, AI-driven diagnostics and treatment plans for
respiratory diseases, especially in underserved regions.

Benefits of the use case:

• The platform directly improves global health by accelerating drug discovery and enabling
personalized treatments for respiratory diseases, which are among the leading causes of
death worldwide.
• Through open-access AI tools and certification programs, the project trains medical
professionals in organoid technology, fostering a new generation of researchers
equipped to tackle future pandemics.
• By integrating biotech and AI, the platform drives pharmaceutical innovation, setting new
standards for drug development and healthcare delivery.
• Collaborations with WHO, Institut Pasteur, and ASEAN health agencies ensure global
knowledge sharing and equitable access to AI-driven healthcare solutions, particularly
for developing countries.

Partners

HKU-Pasteur C2i (Virology expertise); Institut Pasteur (Vaccine R&D); Gavi, the Vaccine Alliance
(Global health equity)

143